Myovant Sciences to Participate in Two Upcoming Investor Conferences

BASEL, Switzerland, Aug. 28, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced its participation in the following upcoming investor conferences:  

• Baird 2018 Global Healthcare Conference in New York. Lynn Seely, M.D., Myovant's President and Chief Executive Officer, will present on Wednesday, September 5, 2018, in a session scheduled to begin at 4:20 p.m. ET. The presentation will be featured in a live webcast and can be accessed via the Events page under the Investors and Media section of Myovant's website at www.myovant.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following the conference.
• Citi's 13^th Annual Biotech Conference in Boston. Myovant will host meetings with investors at the conference on Thursday, September 6, 2018.

About Myovant Sciences
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases. Myovant's goal is to be the leading global biopharmaceutical company focused on treating women's health and endocrine diseases in areas of high unmet medical need. Myovant's lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant has initiated three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 and 2), two in women with endometriosis-associated pain (SPIRIT 1 and 2), and one in men with advanced prostate cancer (HERO). Myovant is also developing MVT-602, a kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Takeda Pharmaceuticals International AG has granted Myovant an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries where Takeda retains exclusive rights) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide. Over time, Myovant intends to expand its development pipeline to include other potential treatments for women's health and endocrine diseases. For more information, please visit the company's website at www.myovant.com.

Investor Contact:
Frank Karbe
Chief Financial Officer
Myovant Sciences, Inc.
[email protected]

Media Contact:
Julie Normart
W2O pure
[email protected]  
415.946.1087 

SOURCE Myovant Sciences